Skip to main content

Table 1 Treatment regimens in Arm A

From: STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

A. Doses in FOLFIRI-cetuximab regimen
H0 Cetuximab 400 mg/m2 /2 h IV infusion (first dose), then 250 mg/m2 /1 h at subsequent IV infusions, every week
or
Cetuximab 500 mg/m2 /2 h IV infusion (first dose), then 500 mg/m2 /1 h at subsequent IV infusions, every 2 weeks
H + 1 Irinotecan 180 mg/m2, in 500 ml NaCl 0.9 % solution, 1 h IV infusion
Folinic acid 400 mg/m2 (leucovorin, racemic or L-form 200 mg/m2) in 250 ml glucose 5 % solution, 2 h IV infusion
H + 3 5FU bolus 400 mg/m2 in 100 ml glucose 5 % solution, 15 min IV infusion
H + 3.5 5FU continuous infusion 2400 mg/m2, 46 h IV infusion
B. Doses in modified FOLFOX6-bevacizumab
H0 Bevacizumab 5 mg/kg, 30–60 min IV infusion
H + 1 Oxaliplatin 85 mg/m2 in 250 ml glucose 5 %, 2 h infusion
Folinic acid 400 mg/m2 (racemic, or L-form 200 mg/m2) in 250 ml glucose 5 % solution, 2 h IV infusion
H + 3 5FU bolus 400 mg/m2 in 100 ml glucose 5 % solution, 15 min IV infusion
H + 3.5 5FU continuous infusion 2400 mg/m2, 46 h IV infusion
C. Doses in modified XELOX-bevacizumab
H0 Bevacizumab 5 mg/kg, 30–60 min IV infusion
H + 1 Oxaliplatin 85 mg/m2 in 250 ml glucose 5 %, 2 h infusion
Day 1-8 Capecitabine 1250–1500 mg/m2 bid, from day 1 (in the evening) to day 8 (in the morning)
  1. Cycles every 2 weeks, until disease progression, unacceptable toxicity or withdrawal of consent